Key Highlights
● Third-quarter Revenue rose about 43% to $30.8 million.
● Pharma revenue rose 109.8% to $16.62 million, above half of total revenue.
● Plasma revenue grew 7.5%, a slowdown from 21% in the second quarter.
● The company reported $34.5 million of unrestricted cash and no bank debt.
Paysign, Inc. (NASDAQ:PAYS) has long been associated with prepaid cards for plasma donors, but its third-quarter 2026 results showed that its pharmaceutical patient affordability Business is now the larger contributor. Reported on Nov. 9, 2026, revenue rose about 43% to $30.8 million, and pharma revenue more than doubled. That shift in mix matters for how the payments company may be assessed going forward, particularly as its plasma segment faces a significant customer loss heading into 2027. The quarter therefore offers a useful reference point for separating the momentum in one business from the pressure building in the other.
Latest Company Context
According to a market review of the release, pharma revenue rose 109.8% to $16.62 million in the quarter, moving above half of total revenue. Active pharma programs reached 167, revenue per program increased roughly 32% to about $99,500, and processed claims grew around 55%. Plasma revenue grew 7.5%, a slowdown from 21% in the second quarter and 25% in the first. GAAP Earnings Per Share came in at $0.11 against a $0.10 consensus, gross Margin widened 840 basis points to 64.7%, and Operating Margin rose to 23.8% from 7.3% a year earlier. Paysign reported $34.5 million of unrestricted cash and no bank debt. Management raised full-year gross margin, net income, EPS and adjusted EBITDA guidance for a third consecutive quarter, while only reaffirming its revenue range.
Key Business and index Drivers
The pharma business benefits from copay assistance and affordability programs that drug manufacturers use to support patients, and Paysign earns revenue per program and per processed claim. Growth in program count, combined with higher revenue per program, appears to be driving both the Top Line and the margin expansion, since pharma work carries strong Gross Profit contribution. Management expects 190 to 195 affordability programs by year-end, implying 59 to 64 net additions in 2026 compared with 55 in 2025.
On the plasma side, a customer is moving 113 centers to a bank-affiliated processor. Those centers produced $11.3 million in trailing revenue and $5.2 million in gross profit, and Paysign now expects to end 2026 with 445 to 450 plasma centers. The reaffirmed revenue range implies fourth-quarter revenue of roughly $26.9 million to $29.9 million, flat to lower versus the third quarter. That outlook suggests the plasma transition may weigh on reported growth before pharma gains fully offset it.
What Investors Should Watch
Investors may watch whether pharma program additions keep pace with management's year-end target of 190 to 195, since that figure will shape how much of the plasma revenue gap can be offset. Fourth-quarter results, likely due in early 2027 based on the company's past reporting pattern, should show the first partial effect of the plasma transition, which management estimated at about $1.5 million of revenue and $0.7 million of gross profit in the quarter. Commentary on 2027 guidance may be closely examined, because the full impact of the departed centers lands next year. Other areas of interest could include revenue per plasma center, which rose to $8,187 per month, any new plasma customer wins, and whether the company keeps its gross margin above its earlier 61% to 63% guidance band.
A Growth Driver That Has Shifted
Paysign's third quarter highlighted a business whose growth driver has shifted. Pharma affordability programs are now the larger segment and appear to be lifting margins, while the plasma unit faces a measurable contraction in 2027. How these two trends net out could define the company's next several quarters. Upcoming results and guidance updates may give a clearer picture of whether pharma momentum can absorb the plasma headwind without a sustained slowdown in consolidated growth. Margin trends, rather than revenue alone, may be an equally important signal.






Please wait processing your request...